Xeris Fights to Protect Billion-Dollar Drug Recorlev from Generics

CHICAGO, IL – February 26, 2026 – Xeris Biopharma Holdings has initiated a high-stakes legal battle to defend its blockbuster drug, Recorlev, launching a patent infringement lawsuit against two generic drug manufacturers seeking to market their own versions of the critical therapy for Cushing's syndrome. The lawsuit represents a pivotal moment for the fast-growing company, as it moves to protect a revenue stream projected to reach nearly one billion dollars annually.

The complaint, filed by Xeris subsidiaries in the U.S. District Court for the District of New Jersey, targets Torrent Pharmaceuticals Limited and Somerset Therapeutics, LLC. Both companies have submitted applications to the U.S. Food and Drug Administration (FDA) for approval to produce generic levoketoconazole, the active ingredient in Recorlev. Xeris is seeking an injunction to prevent the manufacture and sale of these generic versions until its patents expire in March 2040.

The Legal Gauntlet: A Hatch-Waxman Showdown

This legal confrontation is unfolding under the framework of the Hatch-Waxman Act, a landmark 1984 law designed to balance the competing interests of pharmaceutical innovation and affordable healthcare. The act provides a pathway for generic drug makers to challenge the patents of brand-name drugs while also granting innovator companies specific tools to defend their intellectual property.

At the heart of the dispute are four patents covering Recorlev that Xeris has listed in the FDA's "Orange Book," a registry of approved drugs and their associated patents. By filing Abbreviated New Drug Applications (ANDAs) with a "Paragraph IV certification," Torrent and Somerset have formally asserted that these patents are either invalid, unenforceable, or will not be infringed by their proposed generic products. This certification is the standard legal trigger for patent litigation in the pharmaceutical sector.

In response to receiving these notice letters, Xeris acted swiftly. The filing of the lawsuit within a 45-day window automatically triggers a 30-month stay, during which the FDA is generally barred from granting final approval to the generic applications. This provides Xeris a crucial period to litigate its case without immediate generic competition, though the litigation itself can often extend beyond this timeframe.

"We are confident in the quality and strength of the intellectual property we have developed for Recorlev," said John P. Shannon, CEO of Xeris Biopharma, in a statement accompanying the announcement. "We have filed this patent infringement lawsuit to vigorously defend our position."

The outcome of such cases is never certain. Generic manufacturers have a history of successfully invalidating patents or proving non-infringement, while innovator companies often secure favorable settlements or outright court victories. The proceedings will likely involve intense legal scrutiny of the patents' claims, the scientific evidence supporting them, and the history of their prosecution at the U.S. Patent and Trademark Office.

A Cornerstone of Xeris's Financial Future

For Xeris Biopharma, the stakes could not be higher. Recorlev, approved by the FDA in late 2021 for treating endogenous Cushing's syndrome, has rapidly become a cornerstone of the company's growth strategy and financial health. Cushing's syndrome is a rare and debilitating endocrine disorder caused by prolonged exposure to high levels of the hormone cortisol, and Recorlev offers a vital therapeutic option for adult patients for whom surgery is not an option or has not been curative.

The drug's commercial performance has been nothing short of explosive. After its launch in early 2022, Recorlev generated $7.4 million in net revenue that year. This figure soared by nearly 300% to $29.5 million in 2023. This impressive trajectory has continued, with revenues doubling in the first half of 2024 compared to the previous year. Analysts and the company itself project this powerful momentum will continue, with some long-term forecasts anticipating Recorlev could become a blockbuster drug, achieving annual net revenues approaching $1 billion by 2035.

This lawsuit is therefore a direct defense of that future. While Recorlev benefits from a seven-year orphan-drug exclusivity period that runs through late 2028, the patents in question extend its market protection for more than an additional decade. Losing this patent shield would expose Recorlev to generic competition far earlier than anticipated, leading to the dramatic price erosion and market share loss that typically follows. Such an outcome would severely impact Xeris's revenue projections, potentially jeopardizing future funding for its research and development pipeline, which includes promising treatments for hypothyroidism and other conditions. For investors, the lawsuit represents a significant risk factor, and its developments will be watched with intense interest.

The Patent's Strength Under Scrutiny

The core of the legal argument will likely focus on the nature of Recorlev itself. The drug, levoketoconazole, is the specific (2S, 4R) enantiomer of ketoconazole, an older drug. In chemistry, enantiomers are mirror-image molecules that can have vastly different biological effects. Innovator companies often patent specific, more effective, or safer enantiomers of existing racemic mixtures (which contain multiple enantiomers).

Xeris's patents—U.S. Patent Numbers 11,020,393, 11,278,547, 11,903,940, and 12,377,096—are built on the unique properties and methods of using this specific form of the molecule. However, the generic challengers, Torrent Pharmaceuticals and Somerset Therapeutics, will argue that these patents do not meet the legal standards for validity. They may contend that isolating and using this particular enantiomer was "obvious" to a person skilled in the field, given the pre-existing knowledge about ketoconazole.

Both challengers are formidable opponents. Torrent Pharmaceuticals is a major Indian multinational with a long and successful track record of bringing generic drugs to the U.S. market, frequently engaging in and winning patent disputes. Somerset Therapeutics, while smaller, is a specialized U.S.-based firm with expertise in developing complex generic products. Their decision to challenge Xeris's patents indicates they believe there are significant vulnerabilities to exploit. The court will have to delve into complex scientific and legal arguments to determine whether Xeris's invention was truly novel and non-obvious enough to warrant two decades of patent protection.

This legal fight highlights a persistent tension in the pharmaceutical industry. The long, expensive, and risky process of developing a new drug—or improving an existing one—is incentivized by the promise of a period of market exclusivity to recoup investment and fund future innovation. At the same time, the healthcare system and patients rely on the eventual entry of lower-cost generics to ensure broad and affordable access to essential medicines. The Recorlev case is the latest chapter in this ongoing balancing act, with the outcome poised to have significant consequences not only for the companies involved but for the patients who depend on this important therapy.